PADOVA STUDY CLUB
Dr Ian Cardarelli Via Luca Belludi n.3, 35123 - 049/8758345
Post n°9 pubblicato il 04 Dicembre 2006 da iancardarelli
Univ. Prof:
Dr. Ian Cardarelli Padova 8-9 Aprile 2007 Complessità del sistema masticatorio: - L’evoluzione dell’organo masticatorio e la sua funzione - Il modello cibernetico dell’organo masticatorio per la diagnosi e per il trattamento Strutture anatomiche - Il Sistema Cranio Mandibolare (SMM) - Le strutture articolari dure - Le strutture legamentose (dell’articolazione) - Le strutture retroarticolari - La muscolatura propria del sistema articolare della masticazione - Il sistema neuromuscolare (SNM). La muscolatura dell’organo masticatorio - Occlusione e Articolazione Funzioni - La masticazione: definizione e trattazione scientifica - Il linguaggio: fisiologia e patofisiologia - La postura: fisiologia e patofisiologia - Estetica oggettiva e soggettiva - La funzione di controllo dello stress (modello di funzione durante il serramento e digrignamento) Diagnosi funzionale clinica - Anamnesi - Analisi funzionale clinica (fisiodiagnostica) - Indagini sui processi motori dei gruppi muscolari antagonisti - Analisi funzionale clinica con ausilio strumentale (condilografia) - Diagnostica supplementare clinica teleradiografia per l’analisi cefalometrica indicativa per la diagnosi ed il piano di trattamento dei pazienti disfunzionali Il corso si rivolge ad Odontoiatri che desiderano approfondire in modo scientifico le problematiche anatomopatologiche dell’apparato masticatorio. Scopo del corso è fornire i presupposti per poter inquadrare correttamente la diagnosi ed impostare un trattamento individualizzato del paziente con problematiche dell’organo masticatorio. Particolare riguardo sarà dato all’aspetto funzionale che ha determinato lo sviluppo e l’evoluzione del sistema masticatorio. L’utilizzo di strumenti come il condilografo, permette, se associato sempre ad una analisi clinica, di approfondire questi aspetti. Verranno fornite esemplificazioni su casi clinici. Conduttore del corso uno dei più autorevoli maestri, il Prof. Slavicek, autore di approfondimenti scientifici e numerose pubblicazioni sull’argomento. Dr. Ian Cardarelli |
Post n°8 pubblicato il 04 Dicembre 2006 da iancardarelli
Prof. Jan Wennstrom |
BONE TISSUE REMODELING I think we should reconsider the dynamics of bone/tissue
Referring to the current knowledge of bone/tissue
1. growth of tissue requires cell division
2. properties of the daughter cell need to be identical
3. these properties of a cell are in accordance with its
4. during cell cycle the DNA doubles and thus ensures
5. to initiate cell division especially during healing,
6. these cytokines need specific receptors on the
7. a cell of a different tissue does not provide these
8. in transplanting tissue pieces to a different
9. in exchanging bone pieces from the hip, the mandible
10. in accordance with its embryologic origin of the
a. skull with the maxilla (forebrain) b. mandible (midbrain) c. skeleton (hindbrain)
11. there are numerous natural blocking membranes
12. in bone this is the periosteum
13. the denudation of periosteum not only leads to
14. an artificial blocking membrane inhibits this
In principle this is it. Of course it’s more
I agree with the suggestion of using a blocking membrane. This membrane separates the signal proteins of the soft tissue from those of the original bone site. It enables an undisturbed regeneration of the bone tissue within its own encysted environment. However, the role of the bone transplant is reduced to
As to your question for anything different: your first
Questions are welcome.
=============================== |
Post n°5 pubblicato il 21 Febbraio 2006 da iancardarelli
PART1 ... The Novartis meeting was a complete emergence in clinical and basic science and problem solving for 2.5 days. Great experience. The company clearly wants to get to the bottom of all this and is just as frustrated as we are with the lack of definitive research. There will be some suggestions coming out of the meeting, and Novartis is wondering whether or not the dental community wants a Proceedings to be published (they worry about appearing to be self-serving, I think). I can say that we were not able to advance our understanding much because so much of the research is anecdotal, but good studies have been started. I don't know how much I am allowed to say now, but I can at least tell you that the Panel will recommend the least possible infection and trauma to the jaws of anyone on a cancer-related bisphosphonate for more than 6 months. Relative to implants, that would tell me that they should not be done in these patients. The Panel will also recommend not stopping the cancer-related bisphosphonates unless there is exposed alveolar bone. You might be surprised to find that in young people and in mice the bisphosphonates seem to help bone healing! The Panel also looked as osteoporosis-related bisphosphonates, but I wasn't on the subgroup that made those up so I need to look at my notes. PART 2 Thanks for the update. This sounds like a responsible corporate forum looking at a big problem and trying to develop sound, evidence-based strategy for these patients. However, we have published guidelines, echoed in several peer-reviewed, independent articles and advisories that state that implants are contraindicated in patients receiving the IV bisphosphonates Aredia and Zometa. All invasive procedures, except the unavoidable, are discouraged for this group. As far as witholding life-extending medication from these patients in hopes of controlling local disease, there is no evidence to support this recommendation. We have previously dealt with this on the list and have discussed the long-term effects of these drugs. With regard to the comment suggesting stopping these preventive cancer treatments when there is exposed bone, this sounds nonsensical: there is almost always exposed bone. That's the problem! The recurring question about Fosamax has also appeared. The patients affected by Fosamax were all, except in an isolated case or two, receiving very high doses intravenously. The garden variety oral Fosamax patient does not fall under these clinical guidelines. |
Post n°4 pubblicato il 28 Novembre 2005 da iancardarelli
|
Inviato da: volandfarm
il 25/03/2009 alle 08:06
Inviato da: lorteyuw
il 25/03/2009 alle 00:07
Inviato da: lorteyuw
il 25/03/2009 alle 00:06
Inviato da: lorteyuw
il 25/03/2009 alle 00:06
Inviato da: lorteyuw
il 24/03/2009 alle 11:47